Novo Nordisk (NVO) announced the European Medicines Agency's CHMP has adopted a positive opinion recommending a label extension for the existing marketing authorisation for Ozempic, to introduce a new dose of 2.0 mg. Ozempic is currently approved in the EU in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes.
Novo Nordisk expects a final approval by the European Commission within approximately two months. The company expects to launch Ozempic 2.0 mg in the EU in the first half of 2022. The company noted that the label expansion is under regulatory review in the US.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.